Generation Bio Co expected to post a loss of 30 cents a share - Earnings Preview

Generation Bio

28/02/2025 11:31

Generation Bio Co GBIO.OQ GBIO.O is expected to show a fall in quarterly revenue when it reports  results on March 4 (estimated) for the period ending December 31 2024

The Cambridge Massachusetts-based  company is expected to report a 13.1% decrease in revenue to $2.5 million from $2.88 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Generation Bio Co is for a loss of 30 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Generation Bio Co is $7.00​, above​ its last closing price of $0.54. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.28
-0.28
-0.23
Beat
18.6
Jun. 30 2024
-0.29
-0.28
-0.31
Missed
-11.3
Mar. 31 2024
-0.40
-0.41
-1.12
Missed
-174.4​
Dec. 31 2023
-0.44
-0.45
-0.53
Missed
-18.2
​​Sep. 30 2023
-0.50
-0.50
-0.43
Beat
14.9
Jun. 30 2023
-0.50
-0.50
-0.47
Beat
5.4​
Mar. 31 2023
-0.45
-0.46
-0.53
Missed
-14.2
Dec. 31 2022
-0.58
-0.58
-0.55
Beat
5

This summary was machine generated February 28 at 11:31 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)